文献速递炎症性肠病

托法替布治疗与溃疡性结肠炎患者血清脂质的轻度可逆性升高相关

Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-05-08

该分析纳入5项全球研究中的1157例溃疡性结肠炎患者,评估托法替布对脂质和主要不良心血管事件的影响。结果显示托法替布组较安慰剂组总胆固醇、高密度脂蛋白胆固醇和低密度脂蛋白胆固醇自基线升高,但低密度脂蛋白胆固醇/高密度脂蛋白胆固醇比值和总胆固醇/高密度脂蛋白胆固醇比值在61周内无显著变化。主要不良心血管事件发生率为0.24/100患者年(95%CI 0.07-0.62),4例事件中3例患者有4个或以上心血管危险因素。

要点

  • 托法替布组较安慰剂组第8周总胆固醇、高密度脂蛋白胆固醇和低密度脂蛋白胆固醇自基线升高。
  • 至第61周托法替布组脂质浓度仍高于安慰剂组,但脂质比值无显著变化。
  • 主要不良心血管事件发生率为0.24/100患者年(95%CI 0.07-0.62),4例事件中3例有4个或以上心血管危险因素。

核心结论

  • 托法替布治疗溃疡性结肠炎患者可见脂质可逆性升高,且与高敏C反应蛋白降低呈负相关,脂质比值或Reynolds风险评分无临床意义变化,主要不良心血管事件不常见且与剂量无关。

研究设计与样本

  • 分析来自5项全球研究的数据,共纳入1157例溃疡性结肠炎患者,包括3项8周诱导研究(1项2期和2项3期,托法替布10 mg每日两次或安慰剂)、1项52周3期维持研究(应答者接受托法替布5或10 mg每日两次或安慰剂)和1项正在进行的长期扩展研究(对诱导或维持治疗应答及不应答者接受托法替布5或10 mg每日两次)。
  • 脂质浓度从诱导基线评估至第61周(维持治疗第52周),计算主要不良心血管事件发生率(每100患者年暴露中≥1次事件的患者数)和Reynolds风险评分。

主要发现

  • 基线及托法替布治疗第8周平均Reynolds风险评分<5%。
  • 第8周时,托法替布组较安慰剂组总胆固醇、高密度脂蛋白胆固醇和低密度脂蛋白胆固醇自基线升高幅度更大。
  • 托法替布组或安慰剂组中,高敏C反应蛋白水平降低与血清脂质浓度升高存在相关性(P<.001)。
  • 至第61周,托法替布组脂质浓度较安慰剂组升高。
  • 61周期间低密度脂蛋白胆固醇/高密度脂蛋白胆固醇比值和总胆固醇/高密度脂蛋白胆固醇比值无显著变化,报告4例主要不良心血管事件,发生率为0.24(95%CI 0.07-0.62),其中3例患者有4个或以上心血管危险因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Tofacitinib is an oral, small-molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We analyzed inflammation, lipid concentrations, and incidence rates of major adverse cardiovascular (CV) events (MACEs) in patients who received tofacitinib in worldwide studies. METHODS: We collected data from 1157 patients who participated in 3 8-week induction studies (1 phase-2 study and 2 phase-3 studies; patients received tofacitinib 10 mg twice daily or placebo), a 52-week phase-3 maintenance study of responders (patients received tofacitinib 5 or 10 mg twice daily or placebo), and an ongoing long-term extension study of patients who did and did not respond to induction or maintenance therapy (patients received tofacitinib 5 or 10 mg twice daily). Lipid concentrations were assessed from induction baseline to week 61 (week 52 of maintenance therapy). We calculated MACE incidence rates (patients with ≥1 event per 100 patient-years of exposure) and Reynolds risk score (RRS; a composite score used to determine CV risk) for patients given tofacitinib vs placebo. RESULTS: The mean RRS was <5% at baseline and week 8 of treatment with tofacitinib. At week 8, there were greater increases from baseline in total cholesterol, high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol in patients given tofacitinib compared with placebo. There were correlations between reduced levels of high-sensitivity C-reactive protein and increased serum concentrations of lipid in patients given tofacitinib or placebo (P < .001). Lipid concentrations were increased in patients given tofacitinib vs patients given placebo through week 61. Overall, ratios of low-density lipoprotein cholesterol to HDL-c and total cholesterol to HDL-c did not change significantly over the 61-week period. Four MACEs were reported; the incidence rate was 0.24 (95% CI, 0.07-0.62) and 3 of these patients had 4 or more CV risk factors. CONCLUSIONS: In an analysis of data from 5 trials of patients with UC who received tofacitinib, we found reversible increases in lipids with treatment and inverse correlations with reduced levels of high-sensitivity C-reactive protein. We did not find clinically meaningful changes in lipid ratios or RRS. MACEs were infrequent and not dose-related. Clinicaltrials.gov: A3921063 (NCT00787202); OCTAVE Induction 1 (NCT01465763); OCTAVE Induction 2 (NCT01458951); OCTAVE Sustain (NCT01458574); OCTAVE Open (NCT01470612).

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Sands BE, Taub PR, Armuzzi A, et al. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019. PMID: 31077827. doi:10.1016/j.cgh.2019.04.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。